Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Der p Alutard SQ is a standardized allergen extract used for allergen-specific immunotherapy (allergy vaccination) targeting house dust mite (Dermatophagoides pteronyssinus) allergy. It is administered as a subcutaneous injection and works by gradually exposing the immune system to increasing doses of the allergen to induce immunological tolerance. This process modulates the immune response and reduces allergic symptoms over time. The product is developed primarily for the treatment of allergic rhinitis and asthma caused by house dust mites. The active ingredient consists of purified extracts from house dust mites adsorbed onto aluminium hydroxide as an adjuvant to enhance immune modulation[1][5][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Der p Alutard SQ.